STRUCTURE-ACTIVITY RELATIONSHIPS OF ANTI-OESTROGENS WITH REGARD TO INTERACTION WITH 17β-OESTRADIOL IN THE MOUSE UTERUS AND VAGINA

1971 ◽  
Vol 66 (3) ◽  
pp. 431-447 ◽  
Author(s):  
Lars Terenius

ABSTRACT Anti-oestrogenic substances have been studied systematically in order to get some guides about structure - activity relationships. The substances were tested in the mouse a) for uterotrophic and anti-uterotrophic activities and b) for their capacity to inhibit the uptake of 17β-oestradiol by the uterus and vagina in vitro. A few such in vitro experiments were also carried out in the rat. Only MER-25 was completely devoid of any oestrogenic activity and was able to suppress oestrogenic stimulation completely. U-11,100A and CN-55,945 were partial agonists producing less than total oestrogen antagonism. MRL-37, DMS, meso-butoestrol, oestriol and ent-17β-oestradiol were impeded oestrogens, i. e., produced dose-response curves with shallow slopes. These compounds, except oestriol which was inactive, were weakly anti-uterotrophic. Cis- and trans-clomiphene, ICI-47,699 and ICI-46,474 which are also cis/trans isomers, WSM-4613 and U-11,555A showed no sign of anti-oestrogenic activity. All the tested substances suppressed the binding of 17β-oestradiol to the mouse uterus and vagina. The impeded oestrogens were generally very potent. However, their inhibitory action was of short duration since they were easily washed out. The remaining compounds (dialkylamino-alkyl-ether derivatives) were generally very firmly bound to the target tissues, the binding being even firmer than that of the oestrogens 17β-oestradiol or meso-hexoestrol. Possible mechanisms of actions of the two kinds of anti-oestrogens are presented. A model explaining the impeded uterotrophic response is also given.

Parasitology ◽  
1997 ◽  
Vol 114 (5) ◽  
pp. 455-465 ◽  
Author(s):  
M. K. GRAHAM ◽  
I. FAIRWEATHER ◽  
J. G. McGEOWN

The effects of a range of FMRFamide-related peptides (FaRPs) on isometric contractility were tested using isolated muscle strips from the liver fluke, F. hepatica. The neuropeptides tested were the molluscan FaRPs, FMRFamide and FLRFamide, the turbellarian FaRPs, RYIRFamide and GYIRFamide, the cestode peptides, NPF and GNFFRFamide, and the nematode FaRPs, AF-1 (KNEFIRFamide), AF-2 (KHEYLRFamide), AF-8 (KSAYMRFamide), and PF-4 (KPNFIRFamide). Dose-response experiments were undertaken at a concentration range of 5 nM–5 μM for all of the neuropeptides tested. FMRFamide and AF-8 caused statistically significant increases in the amplitude and frequency of contractions at concentrations of 0·5 μM and 5 μM. FLRFamide and AF-2 also caused significant increases in contraction frequency at concentrations of 0·5 μM and 5 μM, although a significant increase in amplitude of contraction was observed only at a concentration of 5 μM. GYIRFamide increased both amplitude and frequency significantly at concentrations of 50 nM, 0·5 μM and 5 μM. RYIRFamide significantly increased frequency of contractions at concentrations of 0·5 μM and 5 μM, but failed to have a significant effect on contraction amplitude. AF-1 at a concentration of 5 μM increased contraction amplitude, but failed to have an effect on frequency at any of the concentrations used. PF-4 caused a statistically significant increase in both the amplitude and frequency of contractions at a concentration of 5 μM. NPF and GNFFRFamide had no effect on the in vitro motility of F. hepatica over the range of concentrations tested. The results are discussed in the light of possible structure–activity relationships in the FaRPs tested.


Author(s):  
Shensheng Zhao ◽  
Sebastiaan Wesseling ◽  
Bert Spenkelink ◽  
Ivonne M. C. M. Rietjens

AbstractThe present study predicts in vivo human and rat red blood cell (RBC) acetylcholinesterase (AChE) inhibition upon diazinon (DZN) exposure using physiological based kinetic (PBK) modelling-facilitated reverse dosimetry. Due to the fact that both DZN and its oxon metabolite diazoxon (DZO) can inhibit AChE, a toxic equivalency factor (TEF) was included in the PBK model to combine the effect of DZN and DZO when predicting in vivo AChE inhibition. The PBK models were defined based on kinetic constants derived from in vitro incubations with liver fractions or plasma of rat and human, and were used to translate in vitro concentration–response curves for AChE inhibition obtained in the current study to predicted in vivo dose–response curves. The predicted dose–response curves for rat matched available in vivo data on AChE inhibition, and the benchmark dose lower confidence limits for 10% inhibition (BMDL10 values) were in line with the reported BMDL10 values. Humans were predicted to be 6-fold more sensitive than rats in terms of AChE inhibition, mainly because of inter-species differences in toxicokinetics. It is concluded that the TEF-coded DZN PBK model combined with quantitative in vitro to in vivo extrapolation (QIVIVE) provides an adequate approach to predict RBC AChE inhibition upon acute oral DZN exposure, and can provide an alternative testing strategy for derivation of a point of departure (POD) in risk assessment.


1993 ◽  
Vol 45 (8) ◽  
pp. 1605-1612 ◽  
Author(s):  
M.J. Hobbs ◽  
M. Butterworth ◽  
G.M. Cohen ◽  
D.G. Upshall

Sign in / Sign up

Export Citation Format

Share Document